B-cell: A logical target for treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 25, Issue 2, 2007, Pages 318-328

  Youinou, Pierre ^a   Jamin, Christophe ^a   Saraux, Alain ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Autoimmune disease; B cell antigen receptor; B Lymphocyte; CD5; Dendritic cell

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; CD134 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CHEMOKINE; CXCL13 CHEMOKINE; DOUBLE STRANDED DNA ANTIBODY; FINGOLIMOD; GAMMA INTERFERON; IMMUNOGLOBULIN D; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOTOXIN; LYMPHOTOXIN BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RHEUMATOID FACTOR; RITUXIMAB; SPHINGOSINE 1 PHOSPHATE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; CELL FATE; CELL SELECTION; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; EFFECTOR CELL; GERMINAL CENTER; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOREGULATION; LIPID RAFT; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD5; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS;

EID: 34249802634     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. BENNETT SR, FALTA MT, BILL J, KOTZIN BL: Antigen-specific T-cells in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 255-63.
2. STUART JM, CREMER MA, TOWNES AS, KANG AH: Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982; 155: 1-16.
3. WEYAND CM, GORONZY JJ: T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999; 11: 210-7.
4. DAVIDSON A, DIAMOND B: Autoimmune diseases. N Engl J Med 2001; 345: 340-50.
5. YOUINOU P, LE GOFF P, MERDRIGNAC G et al.: The relation between CD5-B-lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 1990; 33: 339-48.
6. LOONEY RJ: Treating human autoimmune disease by depleting B-cells. Ann Rheum Dis 2002; 61: 863-6.
7. EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 2004; 350: 2572-81.
8. LYDYARD PM, MACKENZIE LE, YOUINOU P, DEANE M, JEFFERIS R, MAGEED RA: Specificity and idiotype expression of IgM produced by CD5+ and CD5- cord blood B-cells. Ann NY Acad Sci 1992; 651: 527-35.
9. YOUINOU P, MACKENZIE L, LAMOUR A, MAGEED RA, LYDYARD PM: Human CD5-positive B-cells in lymphoid malignancy and connective tissue disease. Eur J Clin Invest 1993; 23: 139-50.
10. BRÖKER BM, KLAJMAN A, YOUINOU P et al.: Chronic lymphocytic leukemia cells secrete multispecific autoantibodies. J Autoimmun 1988; 1: 469-81.
11. KANTOR A: A new nomenclature for B-cells. Immunol Today 1991; 12: 388-91.
12. YOUINOU P, JAMIN C, LYDYARD PM: CD5 expression in human B-cell populations. Immunol Today 1999; 20: 312-6.
13. KASSIAN MT, IKEMATSU H, CASALI P: Identification and analysis of a novel surface CD5-B-lymphocyte subset producing natural antibodies. J Immunol 1992; 148: 2690-702.
14. YOUINOU P, LYDYARD PM: CD5+B-cells in nonorgan-specific autoimmune diseases: A fresh look. Lupus 2001; 10: 523-5.
15. WORTIS HH, BERLAND O: Cutting edge commentary: origins of B-1 cells. J Immunol 2001; 166: 2163-6.
16. HERZETBERG LA: B-1 cells: the lineage question revisited. Immunol Rev 2000; 175: 9-19.
17. MONTECINO-RODRIGUEZ E, LEATHERS H, DORSHKIND K: Identification of a B-1 B-cell-specified progenitor. Nat Immunol 2006; 7: 293-301.
18. PERS JO, JAMIN C, LYDYARD PM, CHARREIRE J, YOUINOU P: The H2 haplotype regulates the distribution of B-cells into B1a, B1b and B2 subsets. Immunogenetics 2002; 54: 208-11.
19. PERS JO, JAMIN C, YOUINOU P, CHARREIRE J: Role of IL-10 in the distribution of B-cell subsets in the mouse B1 cell population. Eur Cytokine Netw 2003; 14: 178-85.
20. PAAVONEN T, QUARTEY-PAPAFIO R, DELVES PJ et al.: CD5 mRNA expression and autoantibody production in early human B-cells immortalized by EBV. Scand J Immunol 1990; 31: 369-74.
21. PLATER-ZYBERK C, MAINI RN, LAM K, KENNEDY TD, JANOSSY G: A rheumatoid arthritis B-cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum 1985; 28: 971-6.
22. YOUINOU P, MACKENZIE LE, JOUQUAN J, LE GOFF P, LYDYARD PM: CD5-positive B-cells in patients with rheumatoid arthritis: Phorbol ester-mediated enhancement of detention. Ann Rheum Dis 1987; 46: 37-9.
23. DAUPHINÉE M, TOVAR Z, TALAL N: B-cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum 1988; 31:642-7.
24. YOUINOU P, MACKENZIE L, LE MASSON G et al: CD5-expressing B-lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J Autoimmun 1988; 1: 185-94.
25. MARTINI A, MASSA M, DE BENEDETTI F, VIOLA S, NEIROTTI G, BURGIO RG: CD5 positive B-lymphocytes in seronegative juvenile arthritis. J Rheumatol 1990; 17: 932-5.
26. JARVIS JN, KAPLAN J, FINE N: Increase in CD5+ B-cells in juvenile rheumatoid arthritis. Relationship to IgM rheumatoid factor expression and disease activity. Arthritis Rheum 1992; 35:204-7.
27. ANAYA JM, CORREA PA, HERRERA M, ESKDALE J, GALLAGHES G: Interleukin 10 (IL-10) influences autoimmune response in primary Sjögren's syndrome and is linked to IL-10 gene polymorphism. J Rheumatol 2002; 29: 1874-6.
28. CASALI P, BURASTERO SE, NAKAMURA M, INGHIRAMI G, NOTKINS AL: Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236: 77-81.
29. HARDY RR, HAYAKAWA K, SHIMIZU M, YAMASAKI K, KISHIMOTO T: Rheumatoid factor secretion from human Leu-1+ B-cells. Science 1987; 236: 81-3.
30. NAKAMURA M, BURASTERO SE, NOTKINS AL, CASAL P: Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu1)+ B cells are polyreactive. J Immunol 1988; 140: 4180-6.
31. CASALI P, BURASTERO SE, BALOW JE, NOTKINS AL: High-affinity antibodies to ssDNA are produced by CD-B cells in systemic lupus erythematosus patients. J Immunol 1989; 143: 3476-83.
32. CARSETTI R, KOHLER G, LAMERS MC: Transitional B-cells are the target of negative selection in the B-cell compartment. J Exp Med 1995; 181: 2129-40.
33. SIMS GP, ETTINGER R, SHIROTA Y, YARBORO CH, ILLEI GG, LIPSKY PE: Identification and characterization of circulating human transitional B-cells. Blood 2005; 105: 4390-8.
34. ALLMAN D, LINDSLEY RC, DEMUTH W, RUDD K, SHINTON SA, HARDY RR: Resolution of three nonproliferative immature splenic B-cell subsets reveals multiple selection points during peripheral B-cell maturation. J Immunol 2001; 167: 6834-40.
35. CHUNG JB, SILVERSAN M, MONROE JG: Transitional B-cells: step by step towards immune competence. Trends Immunol 2003; 24:343-9.
36. MARTIN F, KEARNEY JF: Marginal-zone B-cells. Nat Rev Immunol 2002; 2: 323-35.
37. CAMACHO SA, KOSCO-VILBOIS MH, BEREK C: The dynamic structure of the germinal center. Immunol Today 1998; 19: 511-4.
38. JACOB J, KASSIR R, KELSOE G: In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J Exp Med 1991; 173: 1165-75.
39. GARCIA DE VINUESA C, GULBRANSON-JUDGE A, KHAN M et al.: Dendritic cells associated with plasmablast survival. Eur J Immunol 1999; 29: 3712-21.
40. CASOLA S, OTIPOBY KL, ALIMZHANOV M et al.: B-cell receptor signal strength determines B-cell fate. Nat Immunol 2004; 5: 317-27.
41. SAITO T, CHIBA S, ICHIKAWA M et al.: Notch2 is preferentially expressed in mature B-cells and indispensable for marginal zone B lineage development. Immunity 2003; 18: 675-85.
42. ARTAVANIS-TCAKONAS S, RAND MD, LAKE RJ: Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-6.
43. WELLER S, FAILI A, GARCIA C et al.: CD40-CD40L independent Ig gene hypermutation suggests a second B-cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001; 98: 1166-70
44. WILLENBROCK K, JUNGNICKEL B, HANSMANN ML, KUPPERS R: Human splenic marginal zone B-cells lack expression of activation-induced cytidine deaminase. Eur J Immunol 2005;35:3002-7.
45. DUNN-WALTERS DK, ISAACSON PG, SPENCER J: Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B-cells suggests that the MGZ of human spleen is a reservoir of memory B-cells. J Exp Med 1995; 182: 559-66.
46. WELLER S, REYNAUD CA, WEILL JC: Splenic marginal zone B-cells in humans: where do they mutate their Ig receptor? Eur J Immunol 2005; 35: 2789-92.
47. WELLER S, BRAUN MC, TAN BK et al.: Human blood IgM "memory" B-cells are circulating splenic marginal zone B-cells harboring a prediversified immunoglobulin repertoire. Blood 2004; 104: 3647-54.
48. WILLIAM J, EULER C, CHRISTENSEN S, SHLOMCHIK ML Evolution of autoantibody responses via somatic hypermutation outside the germinal centers. Science 2002; 297: 2066-70.
49. CAMBRIDGE G, STOHL W, LEANDRO MJ, MIGONE TS, HILBERT DM, EDWARDS JC: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.
50. CINAMON G, MATLOUBIAN M, LESNESKI MJ et al.: Sphingosine 1-phosphate receptor 1 promotes B-cell localization in the splenic marginal zone. Nat Immunol 2004; 5: 713-20.
51. VORA KA, NICHOLS E, PORTER G et al.: Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B-cell displacement. J Leukoc Biol 2005; 78: 471-80.
52. YOUINOU PY, MORROW JW, LETTIN AW, LYDYARD PM, ROITT IM: Specificity of plasma cells in the rheumatoid synovium. I. Immunoglobulin class of antiglobulin-producing cells. Scand J Immunol 1984; 20: 307-15
53. BAETEN D, PEENE I, UNION A et al.: Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001; 44: 2255-62.
54. GRAMMER AC, LIPSKY PE: CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1417-29.
55. TAKEMURA S, BRAUN A, CROWSON C et al.: Lymphoid neogenesis in rheumatoid synovitis.J Immunol 2001; 167: 1072-80.
56. SCHRODER AE, GREINER A, SEYFERT C, BEREK C: Differentiation of B-cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 1996; 93: 221-5.
57. WEYAND CM, KURTIN PJ, GOROAZY JJ: Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001; 159: 787-93.
58. KELSOE G: Life and death in germinal centers (redux). Immunity 1996; 4:107-11.
59. LIU YJ, ARPINC C: Germinal center development. Immunol Rev 1997; 156: 111-26.
60. WILLIAM J, EULER C, SHLOMCHIK MJ: Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: Differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 2005; 174: 6879-87
61. MANZ RA, RADBRUCH A: Plasma cells for a lifetime? Eur J Immunol 2002; 32: 923-7.
62. STEWART JJ, AGOSTO H, LITWIN S et al.: A solution to the rheumatoid factor paradox: Pathologic rheumatoid factors can be tolerized by competition with natural rheumatoid factors. J Immunol 1997; 159: 1728-38.
63. D'ARBONNEAU F, PERS JO, DEVAUCHELLE V, PENNEC Y, SARAUX A, YOUINOU P: BAFF-induced changes in B-cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006; 54: 115-26.
64. BOHNKORST JØ, BJØRGAN MB, THOEN JE, NATVIG JB, THOMPSON KM: Bm1-Bm5 classification of peripheral blood B-cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B-cell subpopulations in patients with primary Sjögren's syndrome. J Immunol 2001; 167: 3610-8.
65. ODENDAHL M, JACOBI A, HANSEN A et al.: Disturbed peripheral B-lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
66. POTTER KN, MOCKRIDGE CI, RAHMAN A et al.: Disturbances in peripheral blood B-cell subpopulations in autoimmune patients. Lupus 2002; 11: 872-7.
67. REPARON-SCHUIJT C, VAN ESCH WEJ, VAN KOOTEN C et al.: Presence of a population of CD20+ CD38- lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis Rheum 2001; 44: 2029-37.
68. REININGER L, WINKLER TH, KALBERER CP, JOURDAIN M, MELCHERS F, ROLINK AG: Intrinsic B-cell defects in NZB and NZW mice contribute to systemic lupus in (NZ-BXNZW) F1 mice. J Exp Med 1996; 184: 853-61.
69. CHAN OTM, HANNUM LG, HABERMAN AM, MADAIO MP, SHLOMCHIK MJ: A novel mouse with B-cells but lacking serum antibody reveals an antibody-dependent role for B-cells in murine lupus. J Exp Med 1999; 189: 1639-48.
70. CHAN O, SHLOMCHIK MJ: A new role for B-cells in systemic autoimmunity: B-cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 51-9.
71. PASPARAKIS M, ALEXOPOULOU L, EPISKOPOU V, KOLLIAS G: Immune and inflammatory responses in TNF-α-deficient mice: A critical recruitement for TNF-α in the formation of primary B-cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1998; 184: 1397-411.
72. GONZALEZ M, MACKAY F, BROWNING JL, KOSCO-VILBOIS MH, NOELLE RJ: The sequential role of lymphotoxin and B-cells in the development of splenic follicles. J Exp Med 1998; 187: 997-1007.
73. FLYNN S, TOELLNER KM, RAYKUNDALIA C, GOODALL M, LANE P: CD4 T-cell cytokine differentiation: The B-cell activation molecule, OX40 ligand, instructs CD4 T-cells to express interleukin-4 and upregulates expression of the chemokine receptor Bbr-1. J Exp Med 1998; 188: 297-304.
74. CHESNUT RW, GREY HM: Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol 1981; 126: 1075-9.
75. SCHULTZ KR, KLARNET JP, GIENI RS, HAY-GLASS KT, GREENBERG PD: The role of B-cells for in vivo T-cell response to a Friend virus-induced leukemia. Science 1990; 249: 921-3.
76. JANEWAY CA JR, RON J, KATZ ME: The B-cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987; 138: 1051-5.
77. MOHAN C, MOREL L, YANG P, WAKELAND EK: Accumulation of splenic B-1a cell with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum 1998; 41: 1652-62.
78. ROOSNEK E, LANZAVECCHIA A: Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B-cells. J Exp Med 1991; 173: 487-9.
79. TAKEMURA S, KLIMIUK PA, BRAUN A, CORONZY JJ, WEYAND CM: T-cell activation in rheumatoid synovium in B-cell-dependent. J Immunol 2001; 167: 4710-8.
80. O'NEILL SK, SHLOMCHIK MJ, GLANT TT, CAO Y, DOODES PD, FINNEGAN A: Antigen-specific B-cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005; 174: 3781-8
81. DUSTIN ML, DUSTIN LB: The immunological relay race: B-cells take antigen by synapse. Nat Immunol 2001; 2: 480-2.
82. NAGAFUCHI H, SUZUKI N, MIZUSHIMA Y, SAKANE T: Constitutive expression of IL-6 receptors and their role in the excessive B-cell function in patients with systemic lupus erythematosus. J Immunol 1993; 151: 6525-34.
83. MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
84. PISTOIA V: Production of cytokines by human B-cells in health and disease. Immunol Today 1997; 18: 343-50.
85. HARRIS DP, HAYNES L, SAYLES PC et al.: Reciprocal regulation of polarized cytokine production by effector B and T-cells. Nat Immunol 2000; 1: 475-82.
86. HARRIS DT, GOODRICH S, MOHRS K, MOHRS M, LUND FE: Cutting edge: the development of IL-4-producing B-cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol 2005; 175: 7103-7.
87. YOUINOU P, DARIDON C, SARAUX A, DEVAUCHELLE V, PERS JO: Is B-cell the conductor of the lymphocyte orchestra in the salivary glands of patients with primary Sjögren's syndrome? Clin Exp Rheumatol 2006; 24: 491-2.
88. LUND FE, GARVY BA, RANDALL TD, HARRIS DP: Regulatory roles for cytokine-producing B-cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54.
89. WOLF SD, DITTEL BN, HARDARDOTTIR F, JANEWAY CA JR: Experimental autoimmune encephalomyelitis induction in genetically B-cell-deficient mice. J Exp Med 1996; 184: 2271-8.
90. FILLATREAU S, SWEENIE CH, MCGEACHY MJ, GRAY D, ANDERTON SM: B-cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-50.
91. PAREKH VV, PRASAD DV, BANERJEE PP, JOSHI BN, KUMAR A, MISHRA GC: B-cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T -cells: Role of TGF-beta 1. J Immunol 2003; 170: 5897-911.
92. MIZOGUCHI A, BHAN AK: A case for regulatory B-cells. J Immunol 2006; 176: 705-10.
93. LAN RY, ANSARI AA, LIAN ZX, GERSHWIN ME: Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005; 4: 351-63.
94. JUSTEMENT LB: Signal transduction via the B-celT antigen receptor: the role of protein tyrosine kinases and protein tyrosine phosphatases. Curr Tp Microbiol Immunol 2000; 245: 1-51.
95. MTSUCHI L, GOLD MR: New views of BCR structure and organization. Curr Opin Immunol 2001; 13: 270-7.
96. HEALY JI, GOODNOW CC: Positive versus negative signalling by lymphocyte antigen receptors. Annu Rev Immunol 1998; 16: 645-70.
97. CRAXTON A, OTIPOBY KL, JIANG A, CLARK EA: Signal transduction pathways that regulate the fate of B-lymphocytes. Adv Immunol 1999; 73: 79-152.
98. HEALY JI, GOODNOW CC: Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol 1998; 16: 645-70.
99. LAM KP, HÜHN R, RAJEWSKY R: In vivo ablation of surface immunoglobulin on mature B-cells by inducible gene targeting results in rapid cell death. Cell 1997; 90: 1073-83.
100. RENAUDINEAU Y, NÉDELLEC S, BERTHOU C, LYDYARD PM, YOUINOU P, PERS JO: Role of B-cell antigen receptor associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia 2005; 19: 223-9.
101. NÉDELLEC S, RENAUDINEAU Y, BERTHOU C et al.: B-cell response surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol 2005; 174: 3749-56.
102. LIOSSIS SMC, KOVACS B, DENNIS G, KAMMER GC: B-cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early transduction events. J Clin Invest 1996; 98: 2549-57.
103. CASCIOLA-ROSEN LA, ANHALT G, ROSEN A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.
104. PERS JO, JAMIN C, LE CORRE R, LYDYARD PM, YOUINOU P: Ligation of CD5 on resting B-cells, but not on resting T-cells, results in apoptosis. Eur J Immunol 1998; 28: 4170-6.
105. JAMIN C, LE CORRE R, LYDYARD PM, YOUINOU P: Anti-CD5 extends the proliferative response of human CD5+ B-cells activated with anti-IgM and interleukin-2. Eur J Immunol 1996; 26: 57-62.
106. RUCK S, LE CORRE R, YOUINOU P, ZOUALI M: Expression of B-cell receptor-associated signaling molecules in human lupus. Autoimmunity 2001; 33: 213-24.
107. INAOKI M, SATO S, WEINTRAUB BC, GOODNOW CC, TEDDER TF: CD 19-regula-ted signaling thresholds control peripheral tolerance and autoantibody production in B-lymphocytes. J Exp Med 1997; 186: 1923-31.
108. SATO S, HASEGAWA M, FUJIMOTO M, TEDDER TF, TAKEHARA K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. Immunol 2000; 165: 6635-43.
109. HIPPEN KL, TZE LE, BEHRENS TW: CD5 maintains tolerance in anergic B-cells. J Exp Med 2000; 191: 883-9.
110. TIEGS SL, RUSSEL DM, NEMAZEE D: Receptor editing in self-reactive bone marrow B-cells. J Exp Med 1993; 177: 1009-20.
111. MEFFRE E, PAPAVASILIOU F, COHEN P et al.: Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B-cells. J Exp Med 1998; 188: 765-72.
112. ITOH K, MEFFRE E, ALBESIANO E et al.: Immunoglobulin heavy chain variable region gene replacement as a mechanism for receptor revision in rheumatoid arthritis synovial tissue B-lymphocytes. J Exp Med 2000; 192: 1151-64.
113. ROCHAS C, JAMIN C, HILLION S et al.: Fibroblast-like synoviocytes from synovial tissue of rheumatoid arthritis induce autore-activity in B-cells. Arthritis Rheum 2006; 54 (Suppl. 9): S509.
114. HILLION S, SARAUX A, YOUINOU P, JAMIN C: Expression of RAGs in peripheral B-cells outside germinal centers is associated with the expression of CD5. J Immunol 2005; 174: 5553-61.
115. PIERCE SK: Lipid rafts and B-cell activation. Nat Rev Immunol 2002; 2: 96-105.
116. CHERUKURI A, CHENG PC, SOHN HW, PIERCE SK: The CD19/CD21 complex functions to prolong B-cell antigen receptor signaling from lipid rafts. Immunity 2001; 14: 169-79.
117. AMAN MJ, TOSELLO-TRAMPONT AC, RAVICHANDRAN K: Fcγ RII B1 /SHIP-mediated inhibitory signaling in B-cells involves lipid rafts. J Biol Chem 2001; 276: 46371-8.
118. FLORES-BORJA F, KABOURIDIS PS, JURY EC, ISENBERG DA, MAGEED RA: Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2006; 56: 291-302.
119. WEINTRAUB BC, JUN JE, BISHOP AC, SHOKAT KM, THOMAS ML, GOODNOW CC: Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. J Exp Med 2000; 191:1443-8.
120. LI H, AYER LM, LYTTON J, DEANS JP: Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003; 278: 42427-34.
121. JANAS E, PRIEST R, MALHOTRA R: Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005; 72:165-75.
122. AACKAY F, BROWNING JL: BAFF: a fundamental survival factor for B-cells. Nat Rev Immunol 2002; 2: 465-75.
123. PERS JO, DARIDON C, DEVAUCHELLE V et al.: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-9.
124. SEYLER TM, PARK YW, TAKEMURA S et al.: BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
125. TAN SM, XU D, ROSCHKE V, PERRY JW et al.: Local production of B-lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.
126. SZODARAY P, JELLESTAD S, OHLSSON TEAGUE M, JONSSON R: Attenuated apoptosis of B-cell activating factor-expressing cells in primary Sjögren's syndrome. Lab Invest 2003; 83: 357-65.
127. DARIDON C, DEVAUCHELLE V, HUTIN P et al.: Aberrant expression of BAFF by B-lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007 in press.
128. DARIDON C, YOUINOW P, PERS JO: BAFF, APRIL, TWE-PRIL: who's who? Autoimmun Rev, 2007 in press.
129. RENAUDINEAU Y, HILLION S, SARAUX A, MAGEED RA, YOUINOU P: An alternative exon 1 of the CD5 gene regulates CD5 expression in human B-lymphocytes. Blood 2005; 106: 2781-9.
130. RENAUDINEAU Y, VALLET S, LE DANTEC C, HILLION S, SARAUX A, YOUINOU P: Characterization of the human CD5 endogenous retrovirus-E in B lymphocytes. Genes Immun 2005; 6: 663-71.
131. VINUESA CG, COOK MC: The molecular basis of lymphoid architecture and B cell responses: Implications for immunodeficiency and immunopathology. Curr Mol Med 2001; 1: 689-725.
132. EDWARDS JC, CAMBRIDGE G: B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.